Abstract
2509 Background: The PI3K/AKT/mTOR signaling pathway is aberrantly activated in a variety of cancers. The combination of ridaforolimus (mTOR inhibitor) and MK-2206 may lead to blockade of the PI3K ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have